RenaissThera Achieves Discovery Milestone in Its Oral Obesity Drug Program

RenaissThera Achieves Discovery Milestone in Its Oral Obesity Drug Program https://www.taxtmi.com/news?id=46128 RenaissThera is advancing orally active small molecule GIPR modulators from in vitro and in vivo Hits into Lead optimization to select IND enabling candidates, while filing for Composition of Matter and utility patents to protect novel modulators and pursuing pre IND studies, partner engagement, and AI driven discovery to expand its obesity and diabetes therapeutic portfolio. en-us Tue, 10 Jun 2025 11:31:03 +0530 Tue, 10 Jun 2025 11:31:03 +0530 TaxTMI RSS Generator RenaissThera Achieves Discovery Milestone in Its Oral Obesity Drug Program https://www.taxtmi.com/news?id=46128 RenaissThera is advancing orally active small molecule GIPR modulators from in vitro and in vivo Hits into Lead optimization to select IND enabling candidates, while filing for Composition of Matter and utility patents to protect novel modulators and pursuing pre IND studies, partner engagement, and AI driven discovery to expand its obesity and diabetes therapeutic portfolio. News - Tue, 10 Jun 2025 11:31:03 +0530 https://www.taxtmi.com/news?id=46128